Linked Life Data

1124373

Source:http://linkedlifedata.com/resource/pubmed/id/1124373

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
1975-6-27
pubmed:abstractText
After a brief introductory discussion of methods generally used in the treatment of overweight (dieting; fasting; behavioral therapy; physical activity), the pharmacology of anorexigenic drugs and the considerations governing their clinical use and indications are discussed. All currently available anorexigens exert their action through nor-adrenergic stimulation at receptor sites located in the hypothalamus (amphetamine and ephedrine derivatives) or in the limbic system (Mazindol). In view of the CNS-stimulatory effect of these agents, drug addiction must be considered a potential hazard of their prolonged use. Since any drug treatment of obesity interferes with the patient's motivation to subject himself to the prolonged and possibly life-long changes in his eating habits and exertional behavior which are mandatory for the achievement of long-term therapeutic success, the use of drugs is rarely indicated in the treatment of obesity and should remain the exception. In view of their additional potential to induce drug addiction, this is particularly true of appetite suppressants.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0036-7672
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
105
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
461-6
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1975
pubmed:articleTitle
[Mode of action and indication for appetite depressants in the treatment of obesity].
pubmed:publicationType
Journal Article, English Abstract